INmune Bio Appoints David Moss CEO, Shifts Focus to Alzheimer's, Oncology

INmune Bio has appointed David J. Moss as its new CEO, signaling a strategic refocus on developing treatments for Alzheimer's disease, Recessive Dystrophic Epidermolysis Bullosa, and oncology, while discontinuing efforts on treatment-resistant depression for XPro. The company released top-line results from its MINDFuL phase 2 trial for Alzheimer's, which missed primary cognitive endpoints overall but showed positive effects in a subset of patients with multiple inflammation biomarkers. These findings, presented at the Alzheimer's Association International Conference, indicated small but consistent benefits of XPro over placebo on several cognitive measures. Financially, INmune Bio reported a Q2 net loss of $24.5 million but maintains cash reserves sufficient to fund operations through mid-2026, aligning with its goal to file for CORDStrom approval by that time. Analyst consensus rates the stock as an 'Outperform' with significant upside potential, despite some valuation models suggesting downside risk. The company is actively engaging investors through conference calls and detailed trial data presentations to underscore progress amid its leadership transition.